

10 October 2025

Notice of 2025 Annual General Meeting & Proxy Form

Pharmx Technologies Limited (ASX:PHX) (the **Company**) attaches a copy of the following documents:

1. Letter to shareholders regarding arrangements for the 2025 Annual General Meeting as sent to Shareholders in lieu of Notice of Meeting;
2. Notice of Annual General Meeting; and
3. Proxy Form.

ENDS

This announcement has been authorised for lodgement by the board of directors.

For further information contact:

Tom Culver

Chief Executive Officer

investor.relations@pharmx.com.au

About Pharmx Technologies Ltd.

Pharmx is ANZ's leading pharmacy ordering platform, providing essential infrastructure for seamless ordering and inventory management. By connecting the largest network of pharmacies, suppliers, and technology vendors, Pharmx facilitates approximately \$20 billion in transactions annually through its robust, high-availability technology platform—driving efficient operations, seamless connectivity, and valuable insights across its ordering, invoicing, and analytics solutions.

Operating in a dynamic and evolving market, Pharmx is positioned for sustained growth, driven by population growth, demographic shifts, and regulatory changes. With a strategic focus on expanding its addressable market, Pharmx leverages its extensive network, proprietary pharmatech solutions, and advanced data capabilities to unlock new revenue opportunities and enhance healthcare outcomes across Australia and New Zealand.

Date:
10/10/2025

Invitation to Pharmx Technologies Limited 2025 Annual General Meeting

Dear Shareholder,

I am pleased to invite you to attend the 2025 Annual General Meeting (the **Meeting**) of Pharmx Technologies Limited (the **Company**), to be held on Tuesday 11 November 2025 commencing at 10.00am (AEDT).

The meeting will be held online and in person at the offices of Automic at Level 5, 126 Phillip Street, Sydney NSW 2000.

You may pre-register for the Meeting at the online platform provided by our share registry, Automic, at: investor.automic.com.au

In order to vote online you will need to login to or register on the Automic shareholder platform as described in the registration and voting guides provided on their website: <https://www.automicgroup.com.au/virtual-agms/>

To facilitate the smooth running of the meeting we encourage you to login in advance of the meeting. The Meeting will commence at 10:00am (AEDT) and you will be able to register your online attendance from 30 minutes prior to the scheduled start time.

In accordance with section 110D Corporations Act 2001 we will not be sending you a hard copy of the Notice of Meeting or Proxy Form by post ahead of the Meeting. Instead, you are able to view and download a copy of the Notice of Meeting and Proxy Form from our website at <https://pharmx.com.au/investor-centre/> or via the ASX announcements platform.

Also available on our website and attached below will be all the information you need to attend the Meeting, including access to the Notice of Meeting, which includes details on how to use the online facility and instructions on how to vote and ask questions ahead of and at the meeting.

For further information on the live voting process please see the Virtual Meeting Registration and Voting Guide at <https://www.automicgroup.com.au/virtual-agms/>

If you have not elected to receive the Company's FY25 Annual Report in hard copy it is available on the Company's website.

Please exercise your opportunity to vote on these important matters. The directors recommend that Shareholders vote in favour of all resolutions, and the Chair intends to vote all available proxies in favour of Resolutions 1-4.

If you are unable to attend the AGM, I encourage you to participate by completing the enclosed Appointment of Proxy Form and lodging it in the manner outlined in the Notice of Meeting.

How to ask questions

Shareholders will be given an opportunity to ask questions at the Meeting; however, we welcome questions from Shareholders before the meeting. Questions should be directed to the Company via email to company.secretary@boardroomlimited.com.au by COB Tuesday 4 November 2025. Questions should relate to matters relevant to the business of the Meeting (including matters arising from the Financial Report, the Directors' Report or the content of the Auditors' Report), general questions regarding the performance, business or management of the Company and relevant questions about the conduct of the audit.

We look forward to your participation in the Meeting.

Thank you,

A handwritten signature in black ink, appearing to read "N. England", with a stylized flourish at the end.

Nick England
Chair

Notice of Annual General Meeting and Explanatory Memorandum

Pharmx Technologies Limited

ACN 000 091 305

Date: Tuesday 11 November 2025

Time: 10:00am (AEDT)

Place: Online via the Automic meeting platform and in person at
Level 5, 126 Phillip Street, Sydney NSW 2000

NOTICE OF 2025 ANNUAL GENERAL MEETING

Notice is given that the 2025 Annual General Meeting of
Pharmx Technologies Limited ACN 000 091 305 (the **Company**)
will be held at Level 5, 126 Phillip Street, Sydney NSW 2000
on Tuesday 11 November 2025 at 10:00am (AEDT)

Dear Shareholder,

I am pleased to invite you to attend the 2025 Shareholders' Annual General Meeting. Enclosed is your Notice for the Annual General Meeting of Pharmx Technologies Limited. The Meeting is being held on Tuesday 11 November 2025 as a hybrid meeting and will commence at 10:00am (AEDT).

A hybrid meeting means that Shareholders may choose to attend in person, or online through an online meeting platform. Pharmx has made the decision to hold the AGM as a hybrid AGM in order to allow as many of our Shareholders as possible to participate.

We encourage all our Shareholders to take the opportunity to participate in this year's AGM either in person or virtually. Our share registry, Automic, will provide access to a live webcast of the AGM which will enable Shareholders to:

- hear the AGM discussion and view the meeting slides;
- vote between the commencement of the meeting and the closure of voting, as announced by the Chair; and
- submit questions during the meeting.

Information on how to register and vote on the meeting platform is included in the "Virtual Participation" section of this Notice.

You will need to log in and pre-register before the meeting. If you are unable to do attend either physically or virtually, we ask that you kindly complete the enclosed proxy form and return it to our share registry, Automic, by email, mail or fax.

Further information on how to do this is set out in the voting section of this Notice and the Online Proxy Lodgement guide attached to this Notice.

Proxies must be received by no later than 10:00 am (AEDT) on Sunday 9 November 2025. If any of the directors are appointed as a proxy, they will vote in accordance with any instructions given to them. If, as the meeting's Chairman, I am given any proxies with discretion as to how to vote, I will vote in favour of each of the items of business to be considered.

I sincerely hope you will join us at the meeting and take advantage of the opportunity to interact with the board and your fellow shareholders.

Yours sincerely,



Nick England

Chairman

BUSINESS OF THE MEETING

Shareholders are invited to consider the following items of business at the Annual General Meeting:

Ordinary Business

FINANCIAL AND RELATED REPORTS

Agenda Item	Financial and Related Reports
Description	To receive and consider the Financial Report of the Company and its controlled entities and the related Directors' and Auditor's Reports in respect of the financial year ended 30 June 2025.

ADOPTION OF REMUNERATION REPORT (NON-BINDING VOTE)

Resolution 1	Adoption of Remuneration Report (non-binding vote)
Description	Shareholders are asked to adopt the Company's Remuneration Report. The Remuneration Report is set out in the 2025 Annual Report and is available at the Company's website (https://pharmx.com.au/). In accordance with section 250R of the Corporations Act, the vote on this Resolution will be advisory only and will not bind the directors or the Company.
Resolution (Advisory)	To consider and, if thought fit, pass the following Resolution as an advisory resolution : <i>"THAT the Remuneration Report of the Company and its controlled entities for the year ended 30 June 2025 be adopted."</i>
Voting Exclusion	<p>The Company will disregard any votes cast on this Resolution:</p> <ul style="list-style-type: none">• by or on behalf of a member of Key Management Personnel (KMP) named in the Remuneration Report for the year ended 30 June 2025, or that KMP's Closely Related Party, regardless of the capacity in which the vote is cast; and• as a proxy by a member of the KMP at the date of the meeting, or that KMP's Closely Related Party. <p>However, the Company will not disregard a vote if it is cast as a proxy for a person who is entitled to vote on this Resolution:</p> <ul style="list-style-type: none">(a) in accordance with the directions of how to vote on the Proxy Form; or(b) by the Chairman of the Meeting pursuant to an express authorisation on the Proxy Form.

ELECTION OF DIRECTOR – MR. ALEXANDER (SANDY) MELLIS

Resolution 2	Election of Director – Mr. Alexander (Sandy) Mellis
Resolution (Ordinary)	<p>To consider and, if thought fit, pass the following Resolution as an ordinary resolution:</p> <p><i>"THAT Mr. Alexander Mellis, who retires as a director of the Company in accordance with ASX Listing Rule 14.4 and clause 13.3 of the Constitution and, being eligible and offering himself for election, be elected as a director of the Company."</i></p>

RE-ELECTION OF DIRECTOR – MR. ANDREW JONATHAN GEORGE NEWBERY (JON NEWBERY)

Resolution 3	Re-election of Director – Mr. Jon Newbery
Resolution (Ordinary)	<p>To consider and, if thought fit, pass the following Resolution as an ordinary resolution:</p> <p><i>"THAT Mr. Jon Newbery, who retires as a director of the Company in accordance with ASX Listing Rule 14.4 and clause 13.2 of the Constitution and, being eligible and offering himself for re-election, be re-elected as a director of the Company."</i></p>

APPROVAL OF ADDITIONAL 10% PLACEMENT CAPACITY

Resolution 4	Approval of additional 10% Placement Capacity
Resolution (Special)	<p>To consider and, if thought fit, pass the following Resolution as a special resolution:</p> <p><i>"THAT for the purposes of the ASX Listing Rule 7.1A and for all other purposes, Shareholders approve the issue of equity securities up to 10% of the issued capital of the Company (at the time of issue) calculated in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 and on the terms and conditions in the Explanatory Memorandum."</i></p>
Voting Exclusion	<p>The Company will disregard any votes cast in favour of the Resolution by or on behalf of any person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the Company), or an associate of that person or those persons.</p> <p>However, this does not apply to a vote cast in favour of the Resolution by:</p> <ul style="list-style-type: none"> • A person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or • The Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or • A holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: <ul style="list-style-type: none"> ○ The beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and

	<ul style="list-style-type: none"> ○ The holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way. <p>As at the date of this Notice of Meeting it is not known who may participate in the proposed issue (if any). On that basis, no Shareholders are currently excluded from voting.</p>
--	---

Virtual Participation

In accordance with the clause 11.4 of the Company's Constitution, the Chairman has determined that the AGM will be held as a hybrid meeting with the option to attend virtually using an online meeting platform powered by Automic.

Shareholders who wish to participate in the AGM virtually may do so from their computer or mobile device by logging onto the Automic platform.

Shareholders with an existing Automic account will be able to view the AGM live, lodge a direct vote in real time and ask questions online.

Shareholders who do not have an account with Automic are strongly encouraged to register for an account as soon as possible and well in advance of the Meeting to avoid any delays on the day of the Meeting.

An account can be created by visiting investor.automic.com.au and then clicking on "register" and following the prompts. Shareholders will require their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) to create an account with Automic.

Instructions for Voting Virtually at the Meeting

1. Open your internet browser and go to investor.automic.com.au
2. Login using your username and password. If you do not already have an account, click "Register" and follow the prompts. Shareholders are encouraged to register prior to the commencement of the Meeting to avoid delays in accessing the virtual platform.
3. After logging in, a banner will appear at the bottom of your screen when the Meeting is open for registration. Click "Register". Alternatively, select Meetings from the left-hand menu.
4. Click on "Join Meeting" and follow the prompts.
5. When the Chair of the Meeting declares the poll open, select the "Voting" dropdown menu on the right-hand side of your screen.
6. Select either the "Full" or "Allocate" option to access your electronic voting card.
7. Follow the prompts to record your voting direction for each resolution and click "Submit votes". For allocated votes, the number of votes submitted must not exceed your remaining available units. Important: Votes cannot be amended once submitted.

For further information on the live voting process please see the Registration and Voting Guide at <https://www.automicgroup.com.au/virtual-agms/>

It is recommended that Shareholders wishing to attend the Meeting login 15-20 minutes prior to the meeting start time.

More information regarding online participation at the AGM (including how to vote and ask questions online during the AGM) is available using the following link: <https://www.automicgroup.com.au/virtual-agms/>

QUESTIONS FROM SHAREHOLDERS

In order to provide an equal opportunity for all Shareholders to ask questions of the board, we ask you to submit in writing any questions to the Company or to the Company's auditor, BDO, in relation to the conduct of the external audit for the year ended 30 June 2025, or the content of its audit report. Please send your questions to:

The Company Secretary, **Pharmx Technologies Limited**, at BoardRoom Pty Limited, Level 8, 210 George Street, Sydney NSW 2000
E. company.secretary@boardroomlimited.com.au

Written questions must be received by no later than **5.00pm (AEDT) on Tuesday 4 November 2025**.

Your questions should relate to matters that are relevant to the business of the Annual General Meeting, as outlined in this Notice of Meeting and Explanatory Memorandum.

In accordance with the *Corporations Act 2001* (Cth), reasonable opportunity will also be provided to Shareholders attending the Annual General Meeting to ask questions about, or make comments upon, matters in relation to the Company including the Remuneration Report.

During the course of the Annual General Meeting, the Chairman will seek to address as many Shareholder questions as reasonably practicable, and where appropriate, will give a representative of the auditor the opportunity to answer written questions addressed to it. However, there may not be sufficient time to answer all questions at the Annual General Meeting. Please note that individual responses may not be sent to Shareholders.

VOTING INFORMATION

Voting by proxy

- (a) A Shareholder entitled to attend and vote at the Annual General Meeting may appoint one proxy or, if the Shareholder is entitled to cast 2 or more votes at the Meeting, 2 proxies, to attend and vote instead of the Shareholder.
- (b) Where 2 proxies are appointed to attend and vote at the Meeting, each proxy may be appointed to represent a specified proportion or number of the Shareholder's voting rights at the Meeting.
- (c) A proxy need not be a Shareholder of the Company.
- (d) A proxy may be an individual or a body corporate. If a body corporate is appointed, the Proxy Form must indicate the full name of the body corporate and the full name or title of the individual representative of the body corporate for the Meeting.
- (e) A proxy form accompanies this Notice. If a Shareholder wishes to appoint more than 1 proxy, they may make a copy of the Proxy Form attached to this Notice. For the Proxy Form to be valid it must be received together with the power of attorney or other authority (if any) under which the form is signed, or a (notarially) **certified** copy of that power of authority by **10:00am (AEDT) on Sunday 9 November 2025**:

Via the <https://investor.automic.com.au/#/loginsah>
Automic online portal
By email meetings@automicgroup.com.au

By post Automic Pty Limited
GPO Box 5193
Sydney NSW 2001

By personal delivery Automic Pty Limited
Level 5
126 Phillip Street
Sydney NSW 2000

By facsimile Within Australia: (02) 8583 3040
Outside Australia: +61 2 8583 3040

Voting and other entitlements at the Annual General Meeting

A determination has been made by the board of the Company under regulation 7.11.37 of the *Corporations Regulations 2001* that Shares in the Company which are on issue at **7.00pm (AEDT) on Sunday 9 November 2025** will be taken to be held by the persons who held them at that time for the purposes of the Annual General Meeting (including determining voting entitlements at the Meeting).

Proxy voting by the Chairman

The *Corporations Amendment (Improving Accountability on Director and Executive Remuneration) Act 2011* (Cth), imposes prohibitions on Key Management Personnel and their Closely Related Parties from voting their Shares (or voting undirected proxies) on, amongst other things, remuneration matters.

However, the Chairman of a Meeting may vote an undirected proxy (i.e. a proxy that does not specify how it is to be voted), provided the Shareholder who has lodged the proxy has given an express voting direction to the Chairman to exercise the undirected proxy, even if the resolution is connected with the remuneration of a member of Key Management Personnel. If you complete a Proxy Form that authorises the Chairman of the Meeting to vote on your behalf as proxy, and you do not mark any of the boxes so as to give him directions about how your vote should be cast, then you will be taken to have expressly authorised the Chairman to exercise your proxy on Resolution 1. In accordance with this express authority provided by you, the Chairman will vote in favour of Resolution 1. If you wish to appoint the Chairman of the Meeting as your proxy, and you wish to direct him how to vote, please tick the appropriate boxes on the form.

The Company's Chairman, Mr Nick England, will chair the Meeting and intends to vote all available undirected proxies in favour of each item of business. If you appoint as your proxy any director of the Company, except the Chairman, or any other Key Management Personnel or any of their Closely Related Parties and you do not direct your proxy how to vote on Resolution 1, they will not vote your proxy on that item of business.

EXPLANATORY MEMORANDUM TO NOTICE OF 2025 ANNUAL GENERAL MEETING

FINANCIAL AND RELATED REPORTS

<i>Item</i>	<i>Financial and related reports</i>
Explanation	<p>Section 317 of the Corporations Act requires the Company's financial report, directors' report and auditor's report for the financial year ended 30 June 2025 to be laid before the Company's 2025 Annual General Meeting. There is no requirement for a formal resolution on this item.</p> <p>The financial report contains the financial statements of the consolidated entity consisting of Pharmx Technologies Limited and its controlled entities.</p> <p>As permitted by the Corporations Act, a printed copy of the Company's 2025 Annual Report has been sent only to those Shareholders who have elected to receive a printed copy. A copy of the 2025 Annual Report is available at the Company's website (https://pharmx.com.au/).</p> <p>The Chairman of the meeting will allow a reasonable opportunity at the Meeting for Shareholders to ask questions. Shareholders will also be given a reasonable opportunity at the meeting to ask the Company's auditor, BDO, questions about its audit report, the conduct of its audit of the Company's financial report for the year ended 30 June 2025, the preparation and content of its audit report, the accounting policies adopted by the Company in its preparation of the financial statements and the independence of BDO in relation to the conduct of the audit.</p>

ADOPTION OF REMUNERATION REPORT (NON-BINDING RESOLUTION)

<i>Resolution 1</i>	<i>Adoption of Remuneration Report (advisory resolution)</i>
Explanation	<p>Shareholders are asked to adopt the Company's Remuneration Report. The Remuneration Report is set out in the Company's 2025 Annual Report and is available at the Company's website (https://pharmx.com.au/).</p> <p>The Remuneration Report:</p> <ul style="list-style-type: none"> ▪ describes the policies behind, and the structure of, the remuneration arrangements of the Company and the link between the remuneration of executives and the Company's performance; ▪ sets out the remuneration arrangements in place for each director and for certain members of the senior management team; and ▪ explains the differences between the basis for remunerating non-executive directors and senior executives, including the Chief Executive Officer. <p>The vote on this item is advisory only and does not bind the directors. The board will take into account the discussion on this item and the outcome of the vote when considering the future remuneration policies and practices of the Company.</p> <p>Voting consequences</p> <p>Under the Corporations Act, if at least 25% of the votes cast on a Remuneration Report resolution are voted against the adoption of the Remuneration Report in two consecutive annual general meetings, the Company will be required to put to Shareholders a resolution proposing the calling of an extraordinary general meeting to consider the appointment of directors of the Company at the second annual general meeting (Spill Resolution).</p> <p>If more than 50% of Shareholders vote in favour of the Spill Resolution, the Company must convene an extraordinary general meeting (Spill Meeting) within</p>

	<p>90 days of the second annual general meeting, at which all of the directors (other than the executive directors) of the Company, would need to stand for re-election.</p> <p>Following the Spill Meeting, those persons whose election or re-election as directors of the Company is approved by the Shareholders will be the directors of the Company.</p> <p>At the Company's previous Annual General Meeting, the votes cast against the Remuneration Report considered at that Annual General Meeting were less than 25%. Accordingly, the Spill Resolution is not relevant for this Annual General Meeting.</p> <p>Shareholders should be aware that any undirected proxies given to the Chairman will be cast by the Chairman and counted in favour of Resolution 1, subject to compliance with the Corporations Act.</p>
Voting Exclusion	A voting exclusion statement applies to this Resolution, as set out in the Notice.
Board Recommendation	As the resolution relates to matters including the remuneration of the directors, the board, as a matter of corporate governance and in accordance with the spirit of section 250R(4) Corporations Act, makes no recommendation regarding this Resolution.
Chairman's available proxies	The Chairman of the Meeting intends to vote all available proxies in favour of the Resolution.

ELECTION OF DIRECTOR – MR. ALEXANDER (SANDY) MELLIS

Resolution 2	<i>Election of Alexander (Sandy) Mellis as a Director of the Company</i>
Explanation	<p>Clause 13.4 of the Constitution states that the directors may elect any eligible person to be a director by resolution, either to fill a casual vacancy or as an addition to the existing directors. Clause 13.4 also states that a director appointed under the rule holds office only until the next general meeting and is then eligible for election.</p> <p>As such, Sandy Mellis, having previously been appointed by the directors on 1 September 2025, retires at the 2025 Annual General Meeting, and being eligible under clause 13.3 of the Constitution, offers himself for election as a director.</p>
About Sandy Mellis	<p>Sandy was appointed to the board by the directors to fill a casual vacancy in September 2025, having previously served as an alternate director to Mr. Dennis Bastas, a former Non-Executive Director of the Company.</p> <p>Sandy's career has seen him develop and manage consumer health brands, and consumer goods businesses in Australia, NZ, UK, USA and Europe. His 25+ years in the industry has provided Sandy with extensive experience in managing large multi-disciplinary teams, with multi-billion-dollar portfolios, across a wide variety of market channels. More recently, Sandy has held the dual role of Chief Commercial Officer of DBG Health, and Chief Executive Officer of Vidacorp, the Consumer Health & Beauty division of DBG Health.</p> <p>Sandy is a member of the Company's Remuneration & Nomination Committee.</p>
Board Recommendation	The board, with Mr. Mellis abstaining, recommends that Shareholders vote in favour of the Resolution.
Chairman's available proxies	The Chairman of the Meeting intends to vote all available proxies in favour of the Resolution.

RE-ELECTION OF DIRECTOR – MR. ANDREW JONATHAN GEORGE NEWBERY (JON NEWBERY)

Resolution 3	<i>Re-Election of Jon Newbery as a Director of the Company</i>
Explanation	<p>Clause 13.2 of the Constitution states that no director may hold office without re-election beyond the third Annual General Meeting following the meeting at which that director was last elected or re-elected. The 2025 Annual General Meeting will be the third Annual General Meeting at which Mr. Newbery has held his role as a director of the Company without re-election.</p> <p>Jon Newbery retires at the 2025 Annual General Meeting and, being eligible under clause 13.2 of the Constitution, offers himself for re-election as a director.</p>
About Jon Newbery	<p>Jon was appointed to the board of the Company in February 2020. Jon is currently the Chief Operating Officer and an Executive Director of the Company and is not considered to be independent.</p> <p>Jon has over 35 years of experience in senior executive and board roles for ASX listed companies operating in the technology, telecommunications, urban services and facilities management sectors. Jon was Interim CFO of Pharmx while Zoe Hillier was on maternity leave, and upon her return in January 2025 has taken over as COO. Jon is also Chairman of Repurpose It, a Victorian-based business focused on the recycling of construction and demolition materials and organics, Chairman of Energy Locals, a national provider of embedded networks to multi dwelling buildings, Chairman of Total Ventilation Hygiene, a leading HVAC service provider with operations throughout Australia and a Non-executive director of Xref Limited, a listed provider of human resources technology solutions.</p> <p>Previously Jon held roles as Head of Corporate Finance (M&A) at Downer EDI Limited, Australia's leading urban services and facilities management provider, the Managing Director of ASX listed Clarity OSS Limited which developed operational support systems for telecommunication operators across the globe and as Chairman of UK based banknote trading system developer IMX Software. Primary areas of expertise include mergers and acquisitions, corporate finance, financial and strategic planning and the implementation and oversight of reporting and corporate governance structures.</p> <p>Jon is a member of the Company's Remuneration & Nomination Committee.</p>
Board Recommendation	The board, with Mr. Newbery abstaining, recommends that Shareholders vote in favour of the Resolution.
Chairman's available proxies	The Chairman of the Meeting intends to vote all available proxies in favour of the Resolution.

APPROVAL OF ADDITIONAL 10% PLACEMENT CAPACITY

Resolution 4	<i>Approval of 10% Placement Capacity (Special Resolution)</i>
Explanation	<p>Background</p> <p>ASX Listing Rule 7.1A provides that an Eligible Entity may seek shareholder approval by special resolution passed at an annual general meeting to have the additional capacity to issue Equity Securities up to 10% of its issued capital (10% Placement Capacity).</p> <p>Subject to Shareholder approval of this Resolution, the number of Shares that the Company will be able to issue under ASX Listing Rule 7.1A is calculated in accordance with the following formula:</p> <p>$(A \times D) - E$</p>

	<p>A = the number of fully paid ordinary securities on issue at the commencement of the relevant period,</p> <ul style="list-style-type: none"> plus the number of fully paid ordinary securities issued in the relevant period under an exception in rule 7.2 other than exception 9, 16 or 17, plus the number of fully paid ordinary securities issued in the relevant period on the conversion of convertible securities within rule 7.2 exception 9 where: <ul style="list-style-type: none"> the convertible securities were issued or agreed to be issued before the commencement of the relevant period; or the issue of, or agreement to issue, the convertible securities was approved, or taken under these rules to have been approved, under rule 7.1 or 7.4, plus the number of fully paid ordinary securities issued in the relevant period under an agreement to issue securities within rule 7.2 exception 16 where: <ul style="list-style-type: none"> the agreement was entered into before the commencement of the relevant period; or the agreement or issue was approved, or taken under these rules to have been approved, under rule 7.1 or rule 7.4, plus the number of any other fully paid ordinary securities issued in the relevant period with approval under rule 7.1 or rule 7.4, plus the number of partly paid ordinary securities that became fully paid in the relevant period, less the number of fully paid ordinary securities cancelled in the relevant period; <p>D = 10%</p> <p>E = the number of Equity Securities issued or agreed to be issued under rule 7.1A.2 in the relevant period where the issue or agreement has not been subsequently approved by the holders of its ordinary securities under rule 7.4.</p> <p>An Eligible Entity is one that, at the time of the annual general meeting:</p> <p>(a) is not included in the S&P/ASX 300 Index; and</p> <p>(b) has a market capitalisation of \$300 million or less.</p> <p>The Company anticipates it will be an Eligible Entity for the purposes of ASX Listing Rule 7.1A at the time of the annual general meeting.</p> <p>Any Equity Securities issued under the 10% Placement Capacity must be in the same class as an existing quoted class of Equity Securities of the Company.</p> <p>At the date of this Notice, the Company currently has only one (1) class of quoted Equity Securities on issue, being Shares.</p> <p>If this Resolution is passed, the Company will be able to issue Equity Securities under the 10% Placement capacity in addition to its 15% limit under ASX Listing Rule 7.1.</p> <p>If this Resolution is not passed, the Company will not have access to the issue capacity offered under ASX Listing Rule 7.1A.</p> <p>Information required by Listing Rule 7.3A</p> <p>In accordance with ASX Listing Rule 7.3A, the information below is provided in relation to this Resolution:</p> <p>(a) Minimum Price</p> <p>The Equity Securities issued must only be for cash consideration and not less than 75% of the volume weighted average price of Equity Securities in that class calculated over the 15 trading days on which trades in that class were recorded</p>
--	---

	<p>immediately before:</p> <ol style="list-style-type: none"> 1) the date on which the price at which the Equity Securities are to be issued is agreed; or 2) if the Equity Securities are not issued within 10 trading days of the date in paragraph (1) above, the date on which the Equity Securities are issued. <p>(b) 10% Placement Period</p> <p>Shareholder approval of the 10% Placement Capacity is valid from the date of the annual general meeting at which approval is obtained and expires on the earliest to occur of:</p> <ol style="list-style-type: none"> 1) The date which is 12 months after the date of the annual general meeting at which the approval was obtained; 2) The time and date of the Company's next annual general meeting; or 3) The time and date of approval by Shareholders of a transaction under ASX Listing Rule 11.1.2 (a significant change to the nature or scale of the Company's activities) or ASX Listing Rule 11.2 (disposal of the Company's main undertaking). <p>(c) Risk of Economic and Voting Dilution</p> <p>Any issue of Equity Securities under the 10% Placement Capacity will dilute the existing Shareholders' economic and voting interest in the Company. There is a risk that:</p> <ol style="list-style-type: none"> (a) The market price of the Company's Equity Securities in that class may be significantly lower on the issue date than on the date of approval under ASX Listing Rule 7.1A; and (b) The equity securities may be issued at a price that is at a discount to the market price for the Company's Equity Securities on the issue date. <p>The table below sets out the potential dilution scenarios to existing Shareholders calculated in accordance with the formula outlined in ASX Listing Rule 7.1A.2, based on the market price of Shares and the number of Shares on issue as at 2 October 2025.</p> <p>The table also shows:</p> <ol style="list-style-type: none"> (a) two examples where variable "A" has increased, by 50% and 100%. Variable "A" is based on the number of ordinary securities the Company has on issue. The number of ordinary securities on issue may increase as a result of issues of ordinary securities that do not require Shareholder approval (for example, a pro rata entitlements issue to all Shareholders) or future specific placements under ASX Listing Rule 7.1 that are approved at a future Shareholders' Meeting; and (b) two examples of where the issue price of ordinary securities has decreased by 50% and increased by 100% as against the current market price.
--	--

Number of Shares on issue (Variable A in ASX Listing Rule 7.1A.2)		Shares issued – 10% voting dilution	Dilution		
			Issue Price		
			\$0.065	\$0.13	\$0.26
			50% Decrease	Issue Price	100% Increase
			Funds Raised		
Current	598,506,789	59,850,679	\$3,890,294	\$7,780,588	\$15,561,177
50% Increase	897,760,184	89,776,018	\$5,835,441	\$11,670,882	\$23,341,765
100% Increase	1,197,013,578	119,701,358	\$7,780,588	\$15,561,177	\$31,122,353

The table above is based on the following assumptions:

- 1) There are currently 598,506,789 Shares on issue;
- 2) The issue price is the closing price of the Shares on the ASX on 2 October 2025;
- 3) The Company issues the maximum number of Equity Securities under the 10% Placement Capacity;
- 4) No Options or Performance Share Rights are exercised into Shares before the date of issue of the Equity Securities;
- 5) Funds Raised in the table have been rounded to the nearest full dollar;
- 6) The 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue. This is why the voting dilution is shown in each example as 10%;
- 7) The table does not show an example of dilution that may be caused to a particular Shareholder by reason of placement under the 10% Placement Capacity, based on that Shareholder's holding at the date of the Meeting;
- 8) The table shows only the effect of issues of Equity Securities under ASX Listing Rule 7.1A, not under the 15% placement capacity under ASX Listing Rule 7.1; and
- 9) The issue of Equity Securities under the 10% Placement Capacity consists only of Shares.

(d) Purpose of issue under 10% Placement Capacity

The Company intends to use funds raised for ongoing development costs, working capital, investing activities (including possible complimentary business acquisitions or ventures if any are identified and approved by the board), business generation or marketing activities.

(e) Compliance with ASX Listing Rule 7.1A.4

The Company will comply with the disclosure obligations under ASX Listing Rule 7.1A.4 upon issue of any Equity Securities. Namely, the Company must:

- 1) State in its announcement of the proposed issue of Equity Securities under ASX Listing Rule 3.10.3 or in its application for quotation of the Equity Securities under ASX Listing Rule 2.7 that the Equity Securities are being issued under ASX Listing Rule 7.1A; and
- 2) Give to ASX immediately after the issue a list of names of the persons to whom the Company issued the Equity Securities and the number issued to each (not for release to the market).

	<p>(f) Allocation Policy under the 10% Placement Capacity</p> <p>The recipients of the Equity Securities to be issued under the 10% Placement Capacity have not yet been determined as at the date of the Notice but may consist of existing Shareholders or new investors (or both), none of whom will be related parties of the Company.</p> <p>The Company's allocation policy is dependent on the prevailing market conditions at the time of any proposed issue under the 10% Placement Capacity, having regard to the following factors:</p> <ol style="list-style-type: none"> 1) The purpose of the issue; 2) Alternative methods for raising funds available to the Company at that time, including, but not limited to, an entitlement issue or other offer where existing Shareholders may participate; 3) The effect of the issue of Equity Securities on the control of the Company; 4) The financial position and solvency of the Company; and 5) Advice from corporate, financial and broking advisors (if applicable). <p>(g) Previous Issue of Securities under ASX Listing Rule 7.1A</p> <p>The Company has not issued any Equity Securities under Listing Rule 7.1A since it last obtained Shareholder approval at the 2024 AGM on 26 November 2024.</p> <p>(h) Voting Exclusion</p> <p>As at the date of this Notice, the Company has not invited any existing Shareholder to participate in an issue of Equity Securities under ASX Listing Rule 7.1A. Therefore, no existing Shareholders will be excluded from voting on this Resolution.</p>
Special Resolution	This Resolution is a special resolution and therefore requires the approval of 75% of the votes cast by Shareholders present and eligible to vote (in person or by proxy).
Board Recommendation	The board recommends that Shareholders vote in favour of this Resolution.
Chairman's available proxies	The Chairman of the Meeting intends to vote all available proxies in favour of this Resolution.

DEFINITIONS

Annual General Meeting	Means the Annual General Meeting of the Company for 2025 to which the Notice relates.
ASX	Means ASX Limited (ACN 008 624 691) or the Australian Securities Exchange, as the context requires.
ASX Listing Rules	Means the Listing Rules of ASX.
Chairman or Chair	Means the Chairman of the Annual General Meeting
Company or Pharmx	Means Pharmx Technologies Limited ACN 000 091 305.
Constitution	Means the Company's Constitution.
Corporations Act	Means the <i>Corporations Act 2001</i> (Cth).
Closely Related Party (of a member of KMP of an entity)	Has the definition given to it by section 9 of the Corporations Act, and means: <ul style="list-style-type: none"> a) a spouse or child of the member; or b) a child of the member's spouse; or c) a dependant of the member or of the member's spouse; or d) anyone else who is one of the member's family and may be expected to influence the member, or be influenced by the member, in the member's dealings with the entity; or e) a company the member controls; or f) a person prescribed by the regulations for the purposes of this definition.
Equity Securities	Means a share, a unit in a trust, a right to a share or unit in a trust or option, an option over an issued or unissued security, a convertible security, or any security that ASX decides to classify as an equity security.
Explanatory Memorandum	Means this explanatory memorandum accompanying and forming part of the Notice.
Key Management Personnel or KMP	Means those people described as Key Management Personnel in the Remuneration Report and includes all directors
Meeting	Means the Annual General Meeting of the Company for 2025 to which the Notice relates.
Notice	Means this notice of meeting of the Company, including the accompanying Explanatory Memorandum.
Option	Means an option to acquire a fully paid ordinary share in the Company.
Performance Right	Means a contractual right to receive a number of ordinary shares if and when a nominated performance milestone is reached.

Proxy Form	Means the proxy form that is enclosed with and forms part of this Notice
Remuneration Report	Means the remuneration report set out in the Directors' Report section of the Company's annual financial report for the year ended 30 June 2025.
Resolution	Means a resolution set out in this Notice.
Share	Means a fully paid ordinary share in the capital of the Company.
Shareholder	Means a holder of at least one Share in the Company.

Your proxy voting instruction must be received by **10:00am (AEDT) on Sunday, 09 November 2025**, being **not later than 48 hours** before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS

The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: <https://investor.automic.com.au/#/home> Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 - APPOINT A PROXY

If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of Key Management Personnel.

STEP 2 - VOTES ON ITEMS OF BUSINESS

You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY

You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS

Individual: Where the holding is in one name, the Shareholder must sign.

Joint holding: Where the holding is in more than one name, all Shareholders should sign.

Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.

Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.

Email Address: Please provide your email address in the space provided.

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at <https://automicgroup.com.au>.

Lodging your Proxy Voting Form:

Online

Use your computer or smartphone to appoint a proxy at <https://investor.automic.com.au/#/loginsah> or scan the QR code below using your smartphone

Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.



BY MAIL:

Automic
GPO Box 5193
Sydney NSW 2001

IN PERSON:

Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

BY EMAIL:

meetings@automicgroup.com.au

BY FACSIMILE:

+61 2 8583 3040

All enquiries to Automic:

WEBSITE:

<https://automicgroup.com.au>

PHONE:

1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)

